A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
This is a first in human, open-label, single-arm, multicenter dose escalation and expansion Phase 1 study of SHR-A2102 in patients with advanced or metastatic solid tumors. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A2102 and preliminary anti-tumor efficacy
Advanced Or Metastatic Solid Tumor Malignancies
DRUG: SHR-A2102
Dose Limited Toxicity (DLT), 21 Days (first cycle)|Maximum tolerable dose (MTD), 21 Days (first cycle)|Recommended dose for phase II (RP2D), Up to 8 months
Area under the plasma concentration time curve in the dosing interval AUC(TAU) of SHR-A2102, 30 days after last dose|Maximum observed plasma concentration (Cmax) of SHR-A2102, 30 days after last dose|Time of maximum observed plasma concentration (Tmax) of SHR-A2102, 30 days after last dose|Immunogenicity Analysis, ADA, 30 days after last dose|ORR, Objective Response Rate, 24 months|DCR, Disease Control Rate, 24 months|DoR, Duration of Response, 24 months|PFS, Progression-Free-Survival, 24 months|OS, Overall survival, 24 months
This is a first in human, open-label, single-arm, multicenter dose escalation and expansion Phase 1 study of SHR-A2102 in patients with advanced or metastatic solid tumors. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A2102 and preliminary anti-tumor efficacy